
EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.
About this event
EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026
Event type: Medicinal Chemistry, Drug Discovery, Pharmaceutical R&D, Translational Science, Life Sciences Conference
Estimated attendance: 700–1,500+ delegates depending on final program, host city, and sponsor strength. This type of scientific congress usually attracts a concentrated, high-value audience rather than mass footfall.
Overall buyer profile: This is a highly specialized, research-led conference focused on medicinal chemistry and drug discovery. The best buyers are not general attendees; they are people and organizations directly involved in molecule design, lead optimization, preclinical development, translational research, and pharma innovation. The strongest audience is typically made up of pharmaceutical companies, biotech firms, CROs, academic research groups, and platform technology providers.
1️⃣ Who attends: Buyers / Attendees
This event attracts a technical, scientific, and innovation-driven audience. The most relevant attendees are decision-makers and influencers involved in drug discovery and medicinal chemistry workflows. It is especially useful for companies selling research tools, software, lab technologies, assay systems, analytical instruments, CRO services, AI-driven drug discovery platforms, and scientific consulting.
Main attendee groups:
- Medicinal chemists, senior scientists, and principal investigators
- Drug discovery directors, heads of chemistry, and R&D leaders
- Pharma innovation teams and translational research managers
- Biotech founders, CSOs, and research program managers
- Preclinical development and lead optimization specialists
- Computational chemists, structural biologists, and bioinformatics teams
- CRO and CDMO business development leaders
- Analytical chemistry, screening, and assay development professionals
- Academic researchers, postdocs, and graduate-level scientists
- Vendors supplying instruments, reagents, lab automation, and software
The strongest buyers are usually not end consumers. They are organizations with budgets for scientific services, lab infrastructure, partnerships, licensing, compound libraries, and discovery platforms. That makes this event very valuable for B2B outreach.
2️⃣ Where the show is happening + attendee geographic origin
Event location: The final venue may vary depending on the host city selected for 2026. This conference series is usually positioned as an international European-style scientific forum with broad cross-border participation.
Attendee geographic origin: The audience is typically international, with strong representation from Europe, the United Kingdom, North America, and selected Asia-Pacific life sciences hubs. A meaningful portion of attendees generally come from:
- Pharmaceutical clusters in Switzerland, Germany, the United Kingdom, France, and the Netherlands
- U.S. biotech and pharma centers such as Boston, San Diego, New Jersey, and the Bay Area
- Academic and research institutions across Europe and North America
- Global CROs and life sciences service providers with cross-border business development teams
Best geographic targeting:
- Global outreach is the right strategy here
- Priority should go to Europe and North America
- Secondary focus on Israel, Singapore, Japan, South Korea, and other advanced research markets
3️⃣ Audience reach: Local / National / Global
Reach type: Global
This is clearly an international scientific conference, not a local trade show. The audience is likely dispersed across several countries and includes both academic and commercial stakeholders. Because of the technical subject matter, the event has a strong global reputation within medicinal chemistry and drug discovery circles.
For list-building purposes, this means the event is suitable for international buyer segmentation, not just one-country targeting. The attendee list can include global scientific buyers, regional business development leaders, and research decision-makers from multiple countries.
4️⃣ Sample buyer company names + websites
Below is a sample buyer-style list of organizations that are highly relevant to this event. These are buyer accounts, not random names. They represent likely purchasers of scientific services, technology, laboratory tools, software, or partnership opportunities related to medicinal chemistry and drug discovery.
| Priority | Company | Website | Best Title to Target | Why This is a Good Buyer Fit |
|---|---|---|---|---|
| 1 | Novartis | novartis.com | Head of Medicinal Chemistry / Director of Drug Discovery / External Innovation Manager | Global pharma leader with continuous demand for discovery platforms, chemistry expertise, and translational partnerships. |
| 2 | Roche | roche.com | Discovery Research Director / Therapeutic Area Lead / Scientific Partnerships Manager | Strong fit for early-stage research, biomarker-driven discovery, and scientific collaboration. |
| 3 | Pfizer | pfizer.com | Vice President, Medicinal Chemistry / Research Program Lead / External R&D Director | Large-scale drug discovery organization with broad interest in chemistry, screening, and platform innovation. |
| 4 | Merck & Co. | merck.com | Head of Discovery Chemistry / Senior Scientist, Lead Optimization / Alliance Manager | Highly relevant for medicinal chemistry, lead optimization, and scientific collaboration. |
| 5 | AstraZeneca | astrazeneca.com | Director, Small Molecule Discovery / Research Collaboration Lead / Chemistry Program Manager | Excellent buyer profile for innovative chemistry, screening, AI platforms, and pipeline development. |
| 6 | GSK | gsk.com | Head of Chemistry / Drug Discovery Strategy Lead / External Research Partnerships Manager | Strong scientific buyer base with ongoing need for discovery tools and partnerships. |
| 7 | Bristol Myers Squibb | bms.com | Director, Discovery Chemistry / Research Project Leader / Innovation Sourcing Manager | Good fit for complex therapeutic research and sourcing of scientific technologies and services. |
| 8 | Sanofi | sanofi.com | Global Head of Medicinal Chemistry / Early Discovery Leader / Scientific Alliance Director | Broad interest in small-molecule discovery, translational science, and collaborative R&D. |
| 9 | Amgen | amgen.com | Senior Director, Discovery Research / Chemistry Platform Lead / External Innovation Manager | Strong biotech-pharma hybrid buyer with deep investment in discovery and platform capabilities. |
| 10 | AbbVie | abbvie.com | Director, Medicinal Chemistry / Therapeutics Research Director / Business Development, Research | Relevant for discovery chemistry, therapeutic innovation, and research collaboration sourcing. |
| 11 | Takeda | takeda.com | Head of Discovery Sciences / Chemistry Program Director / Alliance Management Lead | International buyer with strong R&D and external partnership activity. |
| 12 | BioNTech | biontech.com | Director, Small Molecule Discovery / Translational Research Lead / Scientific Collaboration Manager | Highly innovative biotech with interest in advanced discovery platforms and cross-functional research. |
| 13 | Evotec | evotec.com | Business Development Director / Head of Discovery Services / Chemistry Operations Lead | CRO/platform-science model makes this a strong buyer for tools, services, and technology partnerships. |
| 14 | Charles River Laboratories | criver.com | Vice President, Discovery Services / Medicinal Chemistry Services Lead / Alliance Manager | Excellent CRO buyer for discovery services, chemistry support, and client-facing scientific solutions. |
| 15 | Cytiva | cytivalifesciences.com | Strategic Account Manager / Product Marketing Manager / Scientific Sales Director | Supplier-side buyer for lab technologies, workflows, and research platform integration. |
| 16 | Thermo Fisher Scientific | thermofisher.com | Market Development Manager / Drug Discovery Sales Director / Life Sciences Partnerships Lead | Strong fit for instruments, reagents, analytical systems, and workflow solutions. |
| 17 | WuXi AppTec | wuxiapptec.com | Business Development Director / Head of Discovery Chemistry Services / Strategic Alliances Manager | Major service provider in drug discovery with direct commercial interest in scientific buyer acquisition. |
| 18 | Sotio Biotech | sotio.com | Research Director / Translational Science Lead / Alliance Manager | Biotech buyer with needs in medicinal chemistry, therapeutic innovation, and scientific outsourcing. |
| 19 | C4X Discovery | c4xdiscovery.com | Head of Drug Discovery / Partnering Director / CSO | Discovery-focused organization with a direct need for chemistry-driven partnerships and platforms. |
| 20 | BioCryst Pharmaceuticals | biocryst.com | Senior Director, Discovery Chemistry / R&D Program Lead / Business Development Manager | Small to mid-size pharma profile with strong relevance for drug discovery and scientific collaboration. |
Top 5 buyer samples to prioritize first: Novartis, Roche, Pfizer, AstraZeneca, and Charles River Laboratories. These are the strongest mix of pharma, research, and service buyers with real relevance to the conference theme.
5️⃣ Job profiles, industries & event type
Best job titles to target:
- Head of Medicinal Chemistry
- Director of Drug Discovery
- Senior Scientist, Medicinal Chemistry
- Research Program Director
- Discovery Chemistry Lead
- Vice President, R&D
- Translational Research Director
- Alliance Management Director
- Business Development Director, Life Sciences
- External Innovation Manager
- Principal Scientist, Lead Optimization
- Computational Chemistry Lead
- Screening and Assay Development Manager
- Scientific Partnership Manager
- Laboratory Automation Product Manager
- Drug Discovery Platform Lead
Best industry filters from your industry list:
- Pharmaceuticals
- Biotechnology
- Research
- Hospital & Health Care
- Medical Devices
- Information Technology & Services
- Computer Software
- Information Services
- Management Consulting
- Market Research
- Higher Education
- Education Management
- Professional Training & Coaching
- Laboratories and scientific services can also be inferred through company keywords if industry tags are not exact
Event type classification: Scientific conference, R&D networking event, drug discovery congress, medicinal chemistry forum, partnership-building event, innovation showcase.
6️⃣ Estimated attendance: expected total footfall
Estimated attendance: 700–1,500+ delegates
This range is appropriate for a specialized conference of this type. The event is not built for mass consumer attendance. Instead, it attracts a smaller but much more qualified audience. That means the list may be smaller than a large trade show, but the buyer quality is significantly higher.
Footfall composition may include:
- Scientific delegates and presenters
- Academic attendees and student researchers
- Pharma and biotech exhibitors
- Sponsored solution providers
- Panelists, keynote speakers, and advisory board members
- Business development and partnership teams
7️⃣ Key focus areas & buyer engagement
Key focus areas:
- Medicinal chemistry innovation
- Lead discovery and lead optimization
- Small molecule design and synthesis
- Hit-to-lead workflows
- Computational chemistry and AI-enabled discovery
- Assay development and screening
- Translational science
- Preclinical development strategy
- Scientific partnerships and outsourcing
- Platform technologies for life sciences R&D
Buyer engagement angle: The best engagement strategy is to position the attendee list as a highly targeted scientific and commercial database, not a generic conference list. Buyers attending this event are likely to respond to outreach involving:
- Discovery chemistry solutions
- Analytical and screening platforms
- Scientific software and data tools
- Research collaboration opportunities
- CRO/CDMO services
- Lab automation and workflow optimization
- Specialized lab equipment and reagents
This audience is especially good for companies that can speak the language of science, innovation, and productivity. Generic sales messaging will not work well here.
8️⃣ Client-product fit note
Very important: Please share your client website before finalizing the best buyer list. The ideal accounts for this event depend heavily on the client’s product or service.
Examples:
- If the client sells lab instruments, target pharma and biotech R&D leaders, screening managers, and scientific procurement teams.
- If the client sells software, target computational chemists, discovery informatics leaders, and research platform managers.
- If the client sells CRO/CDMO or consulting services, target biotech founders, alliance managers, and external innovation teams.
- If the client sells reagents, assay kits, or workflow products, target lab heads, assay development teams, and principal scientists.
- If the client sells hiring, staffing, or recruitment solutions, target HR, talent acquisition, and scientific operations leaders in pharma and biotech.
Best next step: Send the client website, product category, and ideal customer profile so the buyer list can be filtered to match real purchase intent.
9️⃣ Final recommendation
This is a strong event for premium B2B attendee-list sales because the audience is highly specialized, professionally relevant, and commercially valuable. While the attendance size may be moderate compared with a large exhibition, the quality of contacts is much higher.
Best buyer segments to collect:
- Pharma R&D leadership
- Medicinal chemistry teams
- Drug discovery directors
- Biotech scientific founders and CSOs
- CRO business development leaders
- Academic researchers and lab heads
- Scientific software, tools, and platform vendors
Quality rating for B2B attendee-list sales: 9/10
Excellent for a highly targeted, research-driven audience. Best suited for clients selling scientific tools, services, software, instruments, consulting, and innovation partnerships.
Data sheet
| Event Name | EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026 |
| Event Date | 22 June 2026 – 25 June 2026 |
| Event Status | Ongoing |
| Venue | Trinity Conference Centre |
| City | Dublin |
| State / Region | County Dublin |
| Country | Ireland |
| Organizer | EFMC and ACS MEDI are strongly indicated by the event branding; specific local organizing entity should be confirmed on the official event page. |
| Official Event Website | See Sources & Verification Notes for official organization and venue links. |
| Event Type | Medicinal chemistry, drug discovery, pharmaceutical R&D, translational science, life sciences conference |
| Primary Category | Medical & Pharma |
| Secondary Applicable Categories | Science & Research; IT & Technology |
| Audience Reach | Likely global specialist reach with strong European and North American scientific participation |
| Estimated Attendance / Expected Footfall | Estimated 700–1,500+ delegates based on specialist medicinal chemistry congress benchmarks and the user-supplied event brief |
| Attendance Data Reliability | Estimated. Attendance figure not publicly confirmed by the organizer in the material available for this report. |
| Main Purpose of Event | To connect medicinal chemistry and drug discovery professionals across pharma, biotech, academia, CROs, platform providers, and translational research teams for scientific exchange, partnership development, and technology evaluation. |
EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026 is a specialist scientific conference centered on medicinal chemistry, lead discovery, molecule optimization, translational science, and the broader pharmaceutical R&D workflow. The event theme and branding indicate a high-level meeting point for medicinal chemists, discovery scientists, biotech innovators, and research leadership rather than a broad commercial expo with general visitor traffic.
From a lead-generation perspective, the event matters because it attracts technically qualified and commercially influential participants involved in early-stage to preclinical drug development decisions. The strongest opportunities are typically with pharmaceutical R&D leaders, biotech platform teams, contract research organizations, translational institutes, and providers of AI drug discovery tools, scientific software, assay platforms, analytical technologies, outsourced chemistry, and partnership-led innovation services.
| Buyer / Attendee Segment | Typical Organizations | Buying Role or Influence | Relevance to Exhibitors / Suppliers |
|---|---|---|---|
| Medicinal chemistry leaders | Pharma R&D groups, biotech discovery teams, translational research programs | Influence platform selection, chemistry outsourcing, compound design workflows, and scientific collaborations | High relevance for CRO services, compound libraries, computational chemistry, analytical instrumentation, and AI platforms |
| Drug discovery directors and heads of chemistry | Mid-size and large pharma, venture-backed biotech, integrated discovery organizations | Approve budgets, evaluate discovery partners, prioritize pipeline-enabling technologies | Very strong fit for enterprise and strategic sales conversations |
| Translational science and preclinical teams | Academic medical research centers, translational institutes, biotech R&D units | Shape assay selection, target validation, preclinical workflow, external study purchasing | High relevance for assays, bioanalytics, in vitro and in vivo services, and translational data tools |
| CRO and outsourcing buyers | Pharma, biotech, university spinouts, virtual biotech companies | Source medicinal chemistry support, hit-to-lead, DMPK, toxicology, and synthesis capacity | High relevance for outsourced research, specialist chemistry, and integrated discovery partnerships |
| Computational chemistry and AI drug discovery teams | Biotech platform companies, pharma informatics teams, digital biology groups | Evaluate software, data infrastructure, modeling tools, and external platforms | Strong fit for software vendors, cloud partners, data providers, and AI solution providers |
| Principal investigators and academic group leaders | Universities, institutes, publicly funded research centers | Influence grant-funded purchasing, collaborative studies, licensing pathways | Strong relevance for instruments, reagents, databases, and translational partnerships |
| Business development and alliance management teams | Pharma, biotech, platform technology firms, CROs | Identify licensing, co-development, and strategic partnership opportunities | Very relevant for partnership-led outreach and meetings |
| Scientific procurement and lab operations stakeholders | Research institutions, pharma labs, biotech facilities | Manage purchasing of instruments, informatics subscriptions, consumables, and specialized service contracts | Good fit for lab vendors and support service providers |
| Investors and technology scouts | Life sciences investors, innovation offices, venture creation teams | Assess commercial potential of platforms and pipeline assets | Relevant for strategic introductions and platform visibility, though not always direct purchasers |
| Geographic Area | Likely Attendee Origin | Buyer Concentration | Notes |
|---|---|---|---|
| Dublin | Local university researchers, biotech professionals, pharma-linked research staff | Moderate to high | Host-city attendance should be reinforced by nearby academic and life sciences communities |
| County Dublin / Greater Dublin Area | Regional R&D, translational science, and laboratory operations attendees | High | Likely concentration of biotech, pharma support services, and research institutes |
| Ireland | National pharma manufacturing, R&D, university, and translational research delegates | High | Ireland’s pharmaceutical and biotech footprint supports strong domestic relevance |
| United Kingdom | Likely inbound scientific and commercial attendees from pharma, biotech, and universities | High | Short travel corridor and strong medicinal chemistry base make the UK a likely feeder market |
| Continental Europe | Scientists and R&D leaders from EFMC-linked networks and European discovery organizations | Very high | Expected core international audience segment based on event branding and topic area |
| North America | Selected pharma, biotech, and ACS-linked scientific participants | Moderate | More concentrated, high-value delegation rather than mass attendance |
| Other international markets | Selective participation from Asia-Pacific and global innovation centers | Low to moderate | Possible where global platform providers, pharma alliances, or invited speakers are involved |
| Reach Level | Assessment | Explanation |
|---|---|---|
| Global | Primary classification | The EFMC and ACS MEDI branding indicates an internationally relevant medicinal chemistry audience, with likely participation from Europe, the UK, Ireland, and North America. |
| European specialist reach | Secondary description | The strongest concentration is likely to be Europe-based medicinal chemistry, drug discovery, and translational research professionals. |
| Buyer Company / Organization | Buyer Type | Why It Is Relevant | Website | Best Job Titles to Target | Evidence Level |
|---|---|---|---|---|---|
| Pfizer | Pharmaceutical company | Major discovery and development organization relevant to medicinal chemistry and translational science | pfizer.com | Head of Medicinal Chemistry, Senior Director Drug Discovery, Procurement Manager R&D | Strong Market Fit, Attendance Not Confirmed |
| Eli Lilly and Company | Pharmaceutical company | Active in small-molecule and discovery programs relevant to conference themes | lilly.com | Director Medicinal Chemistry, Discovery Biology Lead, Strategic Sourcing Manager | Strong Market Fit, Attendance Not Confirmed |
| Novartis | Pharmaceutical company | Global buyer of discovery technologies, CRO services, and translational capabilities | novartis.com | Executive Director Chemistry, Head of Discovery Partnerships, Procurement Category Manager | Strong Market Fit, Attendance Not Confirmed |
| AstraZeneca | Pharmaceutical company | Strong medicinal chemistry, oncology, and translational science relevance | astrazeneca.com | Director Discovery Sciences, Medicinal Chemistry Lead, External Innovation Manager | Strong Market Fit, Attendance Not Confirmed |
| GSK | Pharmaceutical company | Relevant for chemistry platforms, externalized discovery, and R&D collaboration | gsk.com | VP Drug Discovery, Director Medicinal Chemistry, R&D Procurement Lead | Strong Market Fit, Attendance Not Confirmed |
| Boehringer Ingelheim | Pharmaceutical company | Strong fit for discovery chemistry, assay systems, and preclinical workflow providers | boehringer-ingelheim.com | Head of Chemistry, Discovery Procurement Manager, Alliance Manager | Strong Market Fit, Attendance Not Confirmed |
| Johnson & Johnson Innovative Medicine | Pharmaceutical company | Relevant buyer of drug discovery platforms, data tools, and external research capabilities | jnj.com | Scientific Director, Translational Science Lead, Strategic Sourcing Director | Strong Market Fit, Attendance Not Confirmed |
| Evotec | Drug discovery partner / CRO | Highly relevant for integrated discovery, chemistry services, and partnership discussions | evotec.com | SVP Drug Discovery, Business Development Director, Alliance Director | Strong Market Fit, Attendance Not Confirmed |
| WuXi AppTec | R&D services provider | Relevant for outsourced medicinal chemistry, biology, and preclinical support buying and selling activity | wuxiapptec.com | Business Development Director, Head of Discovery Services, Alliance Lead | Strong Market Fit, Attendance Not Confirmed |
| Charles River Laboratories | Preclinical and discovery services provider | Relevant to preclinical buyers and partnership-driven attendees | criver.com | Director Discovery Services, Preclinical Partnerships Lead, Procurement Lead | Strong Market Fit, Attendance Not Confirmed |
| Trinity College Dublin | Academic research institution | Host-city scientific institution with strong relevance to medicinal chemistry and translational research collaboration | tcd.ie | Principal Investigator, Research Centre Director, Lab Operations Manager | Strong Market Fit, Attendance Not Confirmed |
| University College Dublin | Academic research institution | Potential source of translational science attendees and grant-funded purchasing influence | ucd.ie | PI Medicinal Chemistry, Research Program Director, Procurement Officer | Strong Market Fit, Attendance Not Confirmed |
| Priority | Job Title / Function | Department | Seniority Level | Why This Role Matters |
|---|---|---|---|---|
| 1 | Head of Medicinal Chemistry | R&D / Discovery | Director / VP | Direct owner of chemistry strategy, platform evaluation, and external collaboration |
| 2 | Drug Discovery Director | R&D / Discovery | Director | High-value buyer and influencer for integrated discovery capabilities |
| 3 | Principal Scientist / Senior Scientist | Medicinal Chemistry / Biology | Manager / Senior Individual Contributor | Often drives technical shortlisting and vendor recommendation |
| 4 | Translational Science Lead | Translational Research | Director / Senior Manager | Relevant for assay, biomarker, preclinical, and workflow solutions |
| 5 | Director of External Innovation / Alliances | Business Development | Director / VP | Key for partnership-led sales and co-development opportunities |
| 6 | Strategic Sourcing Manager | Procurement | Manager | Important where the sale involves enterprise contracts, CRO outsourcing, or lab platforms |
| 7 | Lab Operations Manager | Laboratory Operations | Manager | Relevant buyer for instrument, software, and operational support solutions |
| 8 | Computational Chemistry Lead | Informatics / Discovery | Senior Manager / Director | Key target for AI, modeling, and scientific data solutions |
| 9 | Business Development Director | Business Development | Director | Common at CROs, platforms, and biotech firms seeking collaborations and outsourced services |
| 10 | Principal Investigator | Academic Research | Faculty / Research Lead | Important for grant-funded purchases, translational partnerships, and early innovation access |
| Priority | Apollo Industry | Why It Fits the Event | Best Buyer Use Case |
|---|---|---|---|
| 1 | Pharmaceuticals | Core buyer base for medicinal chemistry and drug discovery solutions | Platform evaluation, outsourcing, discovery collaboration |
| 2 | Biotechnology | Strong fit for venture-backed and innovation-led discovery organizations | AI discovery, CRO partnerships, assay and chemistry support |
| 3 | Research | Covers translational and scientific institutes participating in preclinical and medicinal chemistry work | Collaborative research, instrumentation, data resources |
| 4 | Higher Education | Universities are important scientific contributors and research buyers | Lab equipment, software, collaboration and grants |
| 5 | Medical Devices | Relevant for analytical, assay, and adjacent translational technology suppliers | Scientific instrumentation and workflow integration |
| 6 | Computer Software | Relevant for molecular modeling, ELN/LIMS, and AI-enabled chemistry tools | Scientific software, workflow digitization, cheminformatics |
| 7 | Information Technology & Services | Supports data platforms, cloud environments, and scientific computing vendors | Data integration, scientific cloud, AI support |
| 8 | Hospital & Health Care | Relevant where translational medicine and clinical-adjacent research institutes are involved | Biomarker and translational workflow partnerships |
| 9 | Management Consulting | Relevant to specialist life sciences and R&D strategy advisors attending for partnership sourcing | Innovation scouting and market intelligence |
| 10 | Events Services | Useful only for partner ecosystem mapping around scientific event sponsors and organizers | Sponsorship and event partnership targeting |
| Metric | Figure | Status | Source / Basis | Notes |
|---|---|---|---|---|
| Estimated total footfall | 700–1,500+ | Estimated | User-supplied event brief and comparable specialist congress benchmark | High-value specialist event; not a mass-footfall expo |
| Exhibitor count | Not publicly confirmed | Unconfirmed | Organizer figure not available in source material reviewed | Could include sponsors, platform vendors, CROs, and instrument providers |
| Buyer count | Not publicly confirmed | Unconfirmed | No official buyer program count identified | Scientific conferences typically do not publish “buyer” counts in trade-show format |
| Speaker count | Not publicly confirmed | Unconfirmed | Agenda count not available in source material reviewed | Expected to be material for a four-day specialist program |
| Sponsor count | Not publicly confirmed | Unconfirmed | No validated sponsor list available for this report | Sponsors would likely include CROs, software vendors, and research suppliers |
| Historical attendance | Not publicly confirmed | Historical / prior-year evidence unavailable in reviewed material | No prior-year verified attendance figure used | Avoiding unsupported carryover claims |
| Focus Area | Typical Buyer Need | Buyer Engagement Opportunity | Relevant Supplier Offering |
|---|---|---|---|
| Medicinal chemistry | Lead optimization, SAR support, synthesis quality, workflow acceleration | Scientific demos, chemistry partnership meetings, technical consultations | CRO chemistry services, synthesis platforms, compound design tools |
| Drug discovery | Hit identification, target validation, integrated discovery workflows | Partnership sourcing and pipeline-enablement discussions | Discovery platforms, assays, screening, integrated CRO support |
| Translational science | Biomarker relevance, preclinical translation, model systems | Research collaboration and grant-linked procurement discussions | Bioanalytical services, translational platforms, disease models |
| AI and computational chemistry | Molecular modeling, prediction, prioritization, design efficiency | Software evaluations and innovation scouting | AI drug discovery, cheminformatics, cloud compute, data tools |
| Analytical and assay technologies | Data quality, throughput, reproducibility, characterization | Instrument and platform discussions with scientific users and lab operations | Analytical instrumentation, assay kits, automation, lab software |
| Partnerships and external innovation | Access to novel science, discovery partners, platform collaborations | Alliance meetings, BD networking, co-development opportunities | Platform licensing, services partnerships, co-research models |
| Factor | Assessment | Explanation |
|---|---|---|
| Buyer relevance | Very High | Audience is highly specialized and aligned with medicinal chemistry, drug discovery, and translational research buying needs. |
| Decision-maker availability | High | Scientific leaders, research directors, and BD stakeholders are likely present, though not all attendees will hold direct procurement authority. |
| Data collection potential | Medium | Scientific conferences often limit public attendee disclosure, reducing list-building transparency versus trade expos. |
| Apollo targeting potential | Very High | Pharma, biotech, research, and software-related segments can be targeted effectively by function and seniority. |
| Geographic targeting potential | High | Ireland, the UK, and Europe provide a practical first-wave prospect geography; North America can be layered in for broader reach. |
| Best outreach approach | High | Use scientific-value messaging, partnership framing, and workflow problem-solving rather than generic event-sales language. |
| Overall lead quality | High | Quality is strong for specialized B2B prospecting, though current-year public attendance validation is limited. |
| Best use case | High | Best for account-based outreach, scientific partnership targeting, and niche R&D buyer profiling rather than mass attendee-list sales. |
| Limitations / risks | Medium | Public attendee confirmation may be scarce; many participants influence buying technically but do not sign contracts directly. |
| Filter Type | Recommended Filters | Purpose |
|---|---|---|
| Apollo industries | Pharmaceuticals; Biotechnology; Research; Higher Education; Medical Devices; Computer Software; Information Technology & Services; Hospital & Health Care | Build the core target universe aligned with medicinal chemistry and translational science |
| Departments | Research, Engineering, Information Technology, Operations, Business Development, Purchasing, Program Management | Reach both technical evaluators and commercial decision-makers |
| Seniority | Director, VP, Head, CXO, Partner, Owner, Manager, Principal | Focus on budget holders and high-influence scientific leaders |
| Job titles | Head of Medicinal Chemistry; Director Drug Discovery; Principal Scientist; Senior Scientist; Head of Chemistry; Translational Science Lead; Director External Innovation; Alliance Manager; Strategic Sourcing Manager; Lab Operations Manager; Computational Chemistry Lead; Business Development Director | Precision targeting by workflow responsibility and buying influence |
| Geography | Ireland, United Kingdom, Germany, Switzerland, France, Netherlands, Belgium, Denmark, Sweden, United States | Prioritize the most likely event-linked and medicinal chemistry-active markets |
| Employee size | 11–50; 51–200; 201–500; 501–1,000; 1,001–5,000; 5,001+ | Capture both venture-backed biotech and enterprise pharma buyers |
| Keywords | medicinal chemistry, drug discovery, lead optimization, translational science, preclinical, cheminformatics, computational chemistry, assay development, hit-to-lead, small molecule, DMPK | Improve relevance where industry labels are too broad |
| Technologies, if relevant | LIMS, ELN, cheminformatics, cloud computing, AI/ML platforms, screening automation | Useful for software, data, and workflow infrastructure targeting |
| Revenue range, if relevant | $1M–$10M, $10M–$50M, $50M–$500M, $500M+ | Segment emerging biotech from enterprise pharma accounts |
| Company type | Public company, private company, nonprofit research institution, university | Support account segmentation by funding and procurement behavior |
| Funding / public company filters, if relevant | Recently funded biotech, publicly listed pharma, venture-backed R&D platform firms | Identify active buyers with current budget or partnership momentum |
| Source | Type | What It Verified | Reliability |
|---|---|---|---|
| European Federation for Medicinal Chemistry and Chemical Biology (EFMC) | Official organization website | Validated EFMC as an official medicinal chemistry conference organization relevant to the event branding | High |
| American Chemical Society (ACS) | Official organization website | Validated ACS as the parent scientific body connected to ACS MEDI branding | High |
| Trinity Conference Centre | Official venue website | Venue reference for Trinity Conference Centre, Dublin | High |
| User-supplied event brief | Provided source material | Confirmed event title, city, region, country, venue, and event date range; supplied attendance estimate and thematic description | Medium to High |
| Subject-matter benchmark analysis | Analyst assessment | Estimated attendance range, likely attendee profile, and Apollo targeting logic based on specialist medicinal chemistry congress norms | Medium |
🎯 Selling to this event's audience? Get a free tailored buyer list
Tell us your work email and our AI instantly builds a buyer list matched to EFMC-ACSMEDI Medicinal Chemistry Frontiers 2026 — the best‑fit companies to target, the exact decision‑maker job titles, and the industry filters that fit what you sell.